Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lakhani, S. R.
Right arrow Articles by Easton, D. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lakhani, S. R.
Right arrow Articles by Easton, D. F.
Journal of Clinical Oncology, Vol 20, Issue 9 (May), 2002: 2310-2318
© 2002 American Society for Clinical Oncology

The Pathology of Familial Breast Cancer: Predictive Value of Immunohistochemical Markers Estrogen Receptor, Progesterone Receptor, HER-2, and p53 in Patients With Mutations in BRCA1 and BRCA2

By Sunil R. Lakhani, Marc J. van de Vijver, Jocelyne Jacquemier, Thomas J. Anderson, Peter P. Osin, Lesley McGuffog, Douglas F. Easton for the Breast Cancer Linkage Consortium

From the Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research and the Royal Marsden Hospital, and Department of Histopathology, Royal Free and University College Medical School, London; Department of Pathology, University of Edinburgh Medical School, Edinburgh; and CRC Genetic Epidemiology Unit, Strangeways Research Laboratories, Cambridge, United Kingdom; the Netherlands Cancer Institute, Antoni van Leeuwenhoek Huis, Amsterdam, the Netherlands; and Department of Genetic Oncology and Cancer Control, Paoli Calmettes Institute, Marseille, France.

Address reprint requests to Sunil R. Lakhani, MD, The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, Mary-Jean Mitchell Green Building, Chester Beatty Laboratories, Fulham Road, London SW3 6JB, United Kingdom; email: lakhani{at}icr.ac.uk

PURPOSE: The morphologic and molecular phenotype of breast cancers may help identify patients who are likely to carry germline mutations in BRCA1 and BRCA2. This study evaluates the immunohistochemical profiles of tumors arising in patients with mutations in these genes.

MATERIALS AND METHODS: Samples of breast cancers obtained from the International Breast Cancer Linkage Consortium were characterized morphologically and immunohistochemically using antibodies to estrogen receptor, progesterone receptor, HER-2 (c-erbB-2 oncogene), and p53 protein.

RESULTS: Breast cancers in patients with BRCA1 germline mutations are more often negative for estrogen receptor, progesterone receptor, and HER-2, and are more likely to be positive for p53 protein compared with controls. In contrast, BRCA2 tumors do not show a significant difference in the expression of any of these proteins compared with controls.

CONCLUSION: BRCA1 has a distinctive morphology and immunohistochemical phenotype. The combined morphologic and immunohistochemical data can be used to predict the risk of a young patient harboring a germline mutation in BRCA1. The BRCA2 phenotype is currently not well defined.




This article has been cited by other articles:


Home page
 J. Clin. Pathol.Home page
D S P Tan, C Marchio, and J S Reis-Filho
Hereditary breast cancer: from molecular pathology to tailored therapies
J. Clin. Pathol., October 1, 2008; 61(10): 1073 - 1082.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. G. Newman, K. D. Hadfield, A. Latif, S. A. Roberts, A. Shenton, C. McHague, F. Lalloo, S. Howell, and D. G. Evans
Impaired Tamoxifen Metabolism Reduces Survival in Familial Breast Cancer Patients
Clin. Cancer Res., September 15, 2008; 14(18): 5913 - 5918.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
D. C. Allain
Genetic Counseling and Testing for Common Hereditary Breast Cancer Syndromes: A Paper from the 2007 William Beaumont Hospital Symposium on Molecular Pathology
J. Mol. Diagn., September 1, 2008; 10(5): 383 - 395.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
L. Melchor and J. Benitez
An integrative hypothesis about the origin and development of sporadic and familial breast cancer subtypes
Carcinogenesis, August 1, 2008; 29(8): 1475 - 1482.
[Abstract] [Full Text] [PDF]

Home page
 J. Med. Genet.Home page
A C Antoniou, R Hardy, L Walker, D G Evans, A Shenton, R Eeles, S Shanley, G Pichert, L Izatt, S Rose, et al.
Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics
J. Med. Genet., July 1, 2008; 45(7): 425 - 431.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. A. Rakha, J. S. Reis-Filho, and I. O. Ellis
Basal-Like Breast Cancer: A Critical Review
J. Clin. Oncol., May 20, 2008; 26(15): 2568 - 2581.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
O. Gluz, U. A. Nitz, N. Harbeck, E. Ting, R. Kates, A. Herr, W. Lindemann, C. Jackisch, W. E. Berdel, H. Kirchner, et al.
Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial
Ann. Onc., May 1, 2008; 19(5): 861 - 870.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. B. Spurdle, S. R. Lakhani, S. Healey, S. Parry, L. M. Da Silva, R. Brinkworth, J. L. Hopper, M. A. Brown, D. Babikyan, G. Chenevix-Trench, et al.
Clinical Classification of BRCA1 and BRCA2 DNA Sequence Variants: The Value of Cytokeratin Profiles and Evolutionary Analysis--A Report From the kConFab Investigators
J. Clin. Oncol., April 1, 2008; 26(10): 1657 - 1663.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
G. Arpino, L. Wiechmann, C. K. Osborne, and R. Schiff
Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance
Endocr. Rev., April 1, 2008; 29(2): 217 - 233.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Aaltonen, C. Blomqvist, R.-M. Amini, H. Eerola, K. Aittomaki, P. Heikkila, and H. Nevanlinna
Familial Breast Cancers without Mutations in BRCA1 or BRCA2 Have Low Cyclin E and High Cyclin D1 in Contrast to Cancers in BRCA Mutation Carriers
Clin. Cancer Res., April 1, 2008; 14(7): 1976 - 1983.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. D. Kauff, S. M. Domchek, T. M. Friebel, M. E. Robson, J. Lee, J. E. Garber, C. Isaacs, D. G. Evans, H. Lynch, R. A. Eeles, et al.
Risk-Reducing Salpingo-Oophorectomy for the Prevention of BRCA1- and BRCA2-Associated Breast and Gynecologic Cancer: A Multicenter, Prospective Study
J. Clin. Oncol., March 10, 2008; 26(8): 1331 - 1337.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
M. Fatouros, G. Baltoyiannis, and D. H. Roukos
The Predominant Role of Surgery in the Prevention and New Trends in the Surgical Treatment of Women With BRCA1/2 Mutations
Ann. Surg. Oncol., January 1, 2008; 15(1): 21 - 33.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
L Da Silva, C Clarke, and S R Lakhani
Demystifying basal-like breast carcinomas
J. Clin. Pathol., December 1, 2007; 60(12): 1328 - 1332.
[Abstract] [Full Text] [PDF]

Home page
 J. Histochem. Cytochem.Home page
F. H. Vaz, P. M. Machado, R. D. Brandao, C. T. Laranjeira, J. S. Eugenio, A. H. Fernandes, and S. P. Andre
Familial Breast/Ovarian Cancer and BRCA1/2 Genetic Screening: The Role of Immunohistochemistry as an Additional Method in the Selection of Patients
J. Histochem. Cytochem., November 1, 2007; 55(11): 1105 - 1113.
[Abstract] [Full Text] [PDF]

Home page
 J. Med. Genet.Home page
S Masciari, N Larsson, J Senz, N Boyd, P Kaurah, M J Kandel, L N Harris, H C Pinheiro, A Troussard, P Miron, et al.
Germline E-cadherin mutations in familial lobular breast cancer
J. Med. Genet., November 1, 2007; 44(11): 726 - 731.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Dent, M. Trudeau, K. I. Pritchard, W. M. Hanna, H. K. Kahn, C. A. Sawka, L. A. Lickley, E. Rawlinson, P. Sun, and S. A. Narod
Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence
Clin. Cancer Res., August 1, 2007; 13(15): 4429 - 4434.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. D. Kauff and R. R. Barakat
Risk-Reducing Salpingo-Oophorectomy in Patients With Germline Mutations in BRCA1 or BRCA2
J. Clin. Oncol., July 10, 2007; 25(20): 2921 - 2927.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
N. D. Kauff and K. Offit
Modeling Genetic Risk of Breast Cancer
JAMA, June 20, 2007; 297(23): 2637 - 2639.
[Full Text] [PDF]

Home page
 The OncologistHome page
C. R. James, J. E. Quinn, P. B. Mullan, P. G. Johnston, and D. P. Harkin
BRCA1, a Potential Predictive Biomarker in the Treatment of Breast Cancer
Oncologist, February 1, 2007; 12(2): 142 - 150.
[Abstract] [Full Text] [PDF]

Home page
 J. Med. Genet.Home page
A Smith, A Moran, M C Boyd, M Bulman, A Shenton, L Smith, R Iddenden, E R Woodward, F Lalloo, E R Maher, et al.
Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes and implications for screening
J. Med. Genet., January 1, 2007; 44(1): 10 - 15.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
R. W. Haile, D. C. Thomas, V. McGuire, A. Felberg, E. M. John, R. L. Milne, J. L. Hopper, M. A. Jenkins, A. J. Levine, M. M. Daly, et al.
BRCA1 and BRCA2 Mutation Carriers, Oral Contraceptive Use, and Breast Cancer Before Age 50
Cancer Epidemiol. Biomarkers Prev., October 1, 2006; 15(10): 1863 - 1870.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Chen, E. S. Iversen Jr, and G. Parmigiani
In Reply
J. Clin. Oncol., July 10, 2006; 24(20): 3313 - 3314.
[Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
P van der Groep, A Bouter, R van der Zanden, I Siccama, F H Menko, J J P Gille, C van Kalken, E van der Wall, R H M Verheijen, and P J van Diest
Distinction between hereditary and sporadic breast cancer on the basis of clinicopathological data
J. Clin. Pathol., June 1, 2006; 59(6): 611 - 617.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. A. Oldenburg, K. Kroeze-Jansema, H. Meijers-Heijboer, C. J. van Asperen, N. Hoogerbrugge, I. van Leeuwen, H. F.A. Vasen, A.-M. Cleton-Jansen, J. Kraan, J. J. Houwing-Duistermaat, et al.
Characterization of Familial Non-BRCA1/2 Breast Tumors by Loss of Heterozygosity and Immunophenotyping.
Clin. Cancer Res., March 15, 2006; 12(6): 1693 - 1700.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. Chenevix-Trench, S. Healey, S. Lakhani, P. Waring, M. Cummings, R. Brinkworth, A. M. Deffenbaugh, L. A. Burbidge, D. Pruss, T. Judkins, et al.
Genetic and Histopathologic Evaluation of BRCA1 and BRCA2 DNA Sequence Variants of Unknown Clinical Significance
Cancer Res., February 15, 2006; 66(4): 2019 - 2027.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. A. James, R. Doherty, M. Harris, B. N. Mukesh, A. Milner, M.-A. Young, and C. Scott
Optimal Selection of Individuals for BRCA Mutation Testing: A Comparison of Available Methods
J. Clin. Oncol., February 1, 2006; 24(4): 707 - 715.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Fiegl, S. Millinger, G. Goebel, E. Muller-Holzner, C. Marth, P. W. Laird, and M. Widschwendter
Breast Cancer DNA Methylation Profiles in Cancer Cells and Tumor Stroma: Association with HER-2/neu Status in Primary Breast Cancer
Cancer Res., January 1, 2006; 66(1): 29 - 33.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
Y. Ma, P. Katiyar, L. P. Jones, S. Fan, Y. Zhang, P. A. Furth, and E. M. Rosen
The Breast Cancer Susceptibility Gene BRCA1 Regulates Progesterone Receptor Signaling in Mammary Epithelial Cells
Mol. Endocrinol., January 1, 2006; 20(1): 14 - 34.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Melchor, S. Alvarez, E. Honrado, J. Palacios, A. Barroso, O. Diez, A. Osorio, and J. Benitez
The Accumulation of Specific Amplifications Characterizes Two Different Genomic Pathways of Evolution of Familial Breast Tumors
Clin. Cancer Res., December 15, 2005; 11(24): 8577 - 8584.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. S. Larson, B. L. Schlechter, A. de las Morenas, J. E. Garber, L. A. Cupples, and C. L. Rosenberg
Allele Imbalance, or Loss of Heterozygosity, in Normal Breast Epithelium of Sporadic Breast Cancer Cases and BRCA1 Gene Mutation Carriers Is Increased Compared With Reduction Mammoplasty Tissues
J. Clin. Oncol., December 1, 2005; 23(34): 8613 - 8619.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. Honrado, A. Osorio, J. Palacios, R. L. Milne, L. Sanchez, O. Diez, A. Cazorla, K. Syrjakoski, D. Huntsman, P. Heikkila, et al.
Immunohistochemical Expression of DNA Repair Proteins in Familial Breast Cancer Differentiate BRCA2-Associated Tumors
J. Clin. Oncol., October 20, 2005; 23(30): 7503 - 7511.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
E M Rosen, S Fan, and C Isaacs
BRCA1 in hormonal carcinogenesis: basic and clinical research
Endocr. Relat. Cancer, September 1, 2005; 12(3): 533 - 548.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. R. Lakhani, J. S. Reis-Filho, L. Fulford, F. Penault-Llorca, M. van der Vijver, S. Parry, T. Bishop, J. Benitez, C. Rivas, Y.-J. Bignon, et al.
Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype
Clin. Cancer Res., July 15, 2005; 11(14): 5175 - 5180.
[Abstract] [Full Text] [PDF]

Home page
 INT J SURG PATHOLHome page
A. V. Bassarova, J. M. Nesland, T. Sedloev, W. Lilleby, S. L. Hristova, D. Y. Trifonov, and E. Torlakovic
Simultaneous Bilateral Breast Carcinomas: A Category with Frequent Coexpression of HER-2 and ER-{alpha}, High Ki-67 and bcl-2, and Low p53
International Journal of Surgical Pathology, July 1, 2005; 13(3): 239 - 246.
[Abstract] [PDF]

Home page
 Ann OncolHome page
P. O. Chappuis, E. Donato, J. R. Goffin, N. Wong, L. R. Begin, L. R. Kapusta, J.-S. Brunet, P. Porter, and W. D. Foulkes
Cyclin E expression in breast cancer: predicting germline BRCA1 mutations, prognosis and response to treatment
Ann. Onc., May 1, 2005; 16(5): 735 - 742.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
A.-M. Simeone, C.-X. Deng, G. J. Kelloff, V. E. Steele, M. M. Johnson, and A. M. Tari
N-(4-Hydroxyphenyl)retinamide is more potent than other phenylretinamides in inhibiting the growth of BRCA1-mutated breast cancer cells
Carcinogenesis, May 1, 2005; 26(5): 1000 - 1007.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. A. Narod and K. Offit
Prevention and Management of Hereditary Breast Cancer
J. Clin. Oncol., March 10, 2005; 23(8): 1656 - 1663.
[Full Text] [PDF]

Home page
 Cold Spring Harb Symp Quant BiolHome page
A.N.J. TUTT, C.J. LORD, N. MCCABE, H. FARMER, N. TURNER, N.M. MARTIN, S.P. JACKSON, G.C.M. SMITH, and A. ASHWORTH
Exploiting the DNA Repair Defect in BRCA Mutant Cells in the Design of New Therapeutic Strategies for Cancer
Cold Spring Harb Symp Quant Biol, January 1, 2005; 70(0): 139 - 148.
[Abstract] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
E. Ziv, J. Tice, R. Smith-Bindman, J. Shepherd, S. Cummings, and K. Kerlikowske
Mammographic Density and Estrogen Receptor Status of Breast Cancer
Cancer Epidemiol. Biomarkers Prev., December 1, 2004; 13(12): 2090 - 2095.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. W. M. Loo, D. I. Grove, E. M. Williams, C. L. Neal, L. A. Cousens, E. L. Schubert, I. N. Holcomb, H. F. Massa, J. Glogovac, C. I. Li, et al.
Array Comparative Genomic Hybridization Analysis of Genomic Alterations in Breast Cancer Subtypes
Cancer Res., December 1, 2004; 64(23): 8541 - 8549.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
T. Pal, J. Permuth-Wey, T. Holtje, and R. Sutphen
BRCA1 and BRCA2 Mutations in a Study of African American Breast Cancer Patients
Cancer Epidemiol. Biomarkers Prev., November 1, 2004; 13(11): 1794 - 1799.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Jones, E. Ford, C. Gillett, K. Ryder, S. Merrett, J. S. Reis-Filho, L. G. Fulford, A. Hanby, and S. R. Lakhani
Molecular Cytogenetic Identification of Subgroups of Grade III Invasive Ductal Breast Carcinomas with Different Clinical Outcomes
Clin. Cancer Res., September 15, 2004; 10(18): 5988 - 5997.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
L. Liberman
Breast Cancer Screening with MRI -- What Are the Data for Patients at High Risk?
N. Engl. J. Med., July 29, 2004; 351(5): 497 - 500.
[Full Text] [PDF]

Home page
 J. Med. Genet.Home page
D G R Evans, D M Eccles, N Rahman, K Young, M Bulman, E Amir, A Shenton, A Howell, and F Lalloo
A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO
J. Med. Genet., June 1, 2004; 41(6): 474 - 480.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. R. Lakhani, S. Manek, F. Penault-Llorca, A. Flanagan, L. Arnout, S. Merrett, L. McGuffog, D. Steele, P. Devilee, J. G. M. Klijn, et al.
Pathology of Ovarian Cancers in BRCA1 and BRCA2 Carriers
Clin. Cancer Res., April 1, 2004; 10(7): 2473 - 2481.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. C. Hartmann, A. Degnim, and D. J. Schaid
Prophylactic Mastectomy for BRCA1/2 Carriers: Progress and More Questions
J. Clin. Oncol., March 15, 2004; 22(6): 981 - 983.
[Full Text] [PDF]

Home page
 JCOHome page
J. E. Garber and A.-R. Hartman
Prophylactic Oophorectomy and Hormone Replacement Therapy: Protection at What Price?
J. Clin. Oncol., March 15, 2004; 22(6): 978 - 980.
[Full Text] [PDF]

Home page
 JCOHome page
K. Armstrong, J. S. Schwartz, T. Randall, S. C. Rubin, and B. Weber
Hormone Replacement Therapy and Life Expectancy After Prophylactic Oophorectomy in Women With BRCA1/2 Mutations: A Decision Analysis
J. Clin. Oncol., March 15, 2004; 22(6): 1045 - 1054.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. D. Foulkes, K. Metcalfe, P. Sun, W. M. Hanna, H. T. Lynch, P. Ghadirian, N. Tung, O. I. Olopade, B. L. Weber, J. McLennan, et al.
Estrogen Receptor Status in BRCA1- and BRCA2-Related Breast Cancer: The Influence of Age, Grade, and Histological Type
Clin. Cancer Res., March 15, 2004; 10(6): 2029 - 2034.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
M. El-Tamer, D. Russo, A. Troxel, L. P. Bernardino, R. Mazziotta, A. Estabrook, B.-A. Ditkoff, F. Schnabel, and M. Mansukhani
Survival and Recurrence After Breast Cancer in BRCA1/2 Mutation Carriers
Ann. Surg. Oncol., February 1, 2004; 11(2): 157 - 164.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
W. D. Foulkes, J.-S. Brunet, I. M. Stefansson, O. Straume, P. O. Chappuis, L. R. Begin, N. Hamel, J. R. Goffin, N. Wong, M. Trudel, et al.
The Prognostic Implication of the Basal-Like (Cyclin Ehigh/p27low/p53+/Glomeruloid-Microvascular-Proliferation+) Phenotype of BRCA1-Related Breast Cancer
Cancer Res., February 1, 2004; 64(3): 830 - 835.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
P. D. Ryan, D. A. Haber, K. M. Shannon, B. L. Smith, and M. J. Fan
Case 28-2003 - A 51-Year-Old Premenopausal Woman with Newly Diagnosed Breast Cancer and a Strong Family History of Breast Cancer
N. Engl. J. Med., September 11, 2003; 349(11): 1076 - 1082.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Palacios, E. Honrado, A. Osorio, A. Cazorla, D. Sarrio, A. Barroso, S. Rodriguez, J. C. Cigudosa, O. Diez, C. Alonso, et al.
Immunohistochemical Characteristics Defined by Tissue Microarray of Hereditary Breast Cancer Not Attributable to BRCA1 or BRCA2 Mutations: Differences from Breast Carcinomas Arising in BRCA1 and BRCA2 Mutation Carriers
Clin. Cancer Res., September 1, 2003; 9(10): 3606 - 3614.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. T. Lynch, C. L. Snyder, J. F. Lynch, B. D. Riley, and W. S. Rubinstein
Hereditary Breast-Ovarian Cancer at the Bedside: Role of the Medical Oncologist
J. Clin. Oncol., February 15, 2003; 21(4): 740 - 753.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Ottini, G. Masala, C. D'Amico, B. Mancini, C. Saieva, G. Aceto, D. Gestri, V. Vezzosi, M. Falchetti, M. De Marco, et al.
BRCA1 and BRCA2 Mutation Status and Tumor Characteri